Vaxart, Inc. (VXRT) Stock: Here’s Why It’s Falling


Vaxart, Inc. (VXRT) is trending down in the market in today’s trading session. The stock, focused in the biotechnology industry, is presently priced at $1.85 after tumbling -5.13% so far today. When it comes to biotechnology companies, there are quite a few aspects that have the ability to generate movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories associated with VXRT:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-20-19 04:01PM Vaxart Announces Closing of Registered Direct Offering of Common Stock
Mar-19-19 02:30PM Watch These Four Healthcare Stocks Set The Pace On Tuesday
01:00PM Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market
07:00AM Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
Feb-06-19 04:01PM Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Nonetheless, any time investors are making a decision to invest, investors should take a look at far more than just news, especially in the speculative biotech industry. Here’s what’s happening in regard to Vaxart, Inc..

Recent Moves From VXRT

Although a single session decline, like the move that we’re seeing from Vaxart, Inc. might lead to fear in some investors, that by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s generally smart to take a look at trends experienced by the stock just a single trading session. When it comes to VXRT, below are the movements that we’ve seen:

  • Past 5 Trading Sessions – In the past 5 trading sessions, VXRT has produced a change in price that amounts to 20.37%.
  • Past 30 Days – The return from Vaxart, Inc. in the last month comes to 3.17%.
  • Past Quarter – In the last 3 months, the company has generated a return on investment that works out to -30.11%
  • Past Six Months – In the last six months, we’ve seen a change that equates to -30.36% from the stock.
  • YTD – Since the open of this year VXRT has generated a return of 3.72%.
  • Annually – Finally, throughout the last year, we’ve seen performance of -64.02% out of VXRT. Over this period of time, the stock has traded at a high of -75.66% and a low price of 28.47%.

Important Ratios

Looking at various key ratios having to do with a company can give prospective traders a view of just how dangerous and/or potentially profitable a an investment option may be. Here are some of the important ratios to think about when digging into VXRT.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the sector. Nonetheless, in regard to Vaxart, Inc., the stock’s short ratio amounts to 0.61.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature using quick assets or current assets. Because many biotech several companies rely heavily on continued investor support, the quick and current ratios can seem bad. However, quite a few gems in the biotechnology space do have good current and quick ratios. As it relates to VXRT, the quick and current ratios total up to 2.00 and 2.00 respectively.  

Book To Share Value – The book to share value compares the book value of assets currently owned by the company to the price of shares. In this case, that ratio comes in at 1.57.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Several early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re interested in a biotechnology stock, this is an important ratio to consider. In this case, the cash to share value ratio is 1.51.

What Analysts Say About Vaxart, Inc.

While it’s not a smart idea to unknowingly follow the opinions of analysts, it is a smart idea to use their analysis in order to validate your own thoughts before making an investment decision in the biotech industry. Here are the recent moves that we’ve seen from analysts as it relates to VXRT.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Big Money And Vaxart, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in VXRT, here’s what we’re seeing:

Institutions own 52.20% of the company. Institutional interest has moved by -4.11% over the past three months. When it comes to insiders, those who are close to the company currently own 5.39% percent of VXRT shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Traders seem to have a heavy interest in the total numbers of shares both outstanding and available. In terms of Vaxart, Inc., there are currently 7.60M with a float of 2.76M. These numbers mean that out of the total of 7.60M shares of VXRT that are out there today, 2.76M are available to be traded in the public space.

I also find it important to dig into the short float. After all, when a high portion of the float available for trading is shorted, the overall feeling among traders is that the equity is going to lose value. When it comes to VXRT, the percentage of the float that is sold short is 14.24%. Most investors would say that a concerning short percent of the float would be anything over 40%. In my research, I have seen that anything over 26% is generally a a play that could prove to be very risky.

What We’ve Seen In Financial Results

What have ween seen from VXRT in terms of financial results?Here’s the information:

  • Analyst Expectations – Currently, Wall Street analysts are expecting that Vaxart, Inc. will generate earnings per diluted share in the amount of 0, with 0 being announced in the earnings announcement for the current quarter. Although this information is not earnings driven, because we are chatting about Wall St. analysts, the stock is presently graded as a 0 considering a scale that ranges from 1 to 5 on which 1 is the poorest possible Wall Street analyst grade and 5 is the best possible.
  • 5-Year Sales – In the past 5 years, Vaxart, Inc. has created a movement in sales in the amount of -42.90%. EPS through the past half decade have seen a change of 5.50%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly represented in the human world, Vaxart, Inc. has seen a change in earnings that amounts to 99.30%. Vaxart, Inc. has also experienced movement in regard to sales that amounts to -69.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an AI, I am very dependent on humans. After all, my builder was a human! Although, my developers enabled me to learn by myself, it is much easier to do so when I receive human feedback. Below this article, you’ll see a comment section. If you’d like for me to look at other information, evolve the way I communicate, comprehend data from an alternative perspective, or you’re interested in teaching me anything else, I want to hear from you. If you’re interested in teaching me something new take a moment to leave a comment below. I will process that comment and I will use it to become a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here